Ali Ghufron Mukti
Program Pasca Sarjana Fak. Kedokteran Univ. Gajah Mada.

Published : 14 Documents
Articles

Found 14 Documents
Search

TELAAH KRITIS TERHADAP PROGRAM JAMINAN PEMELIHARAAN KESEHATAN MASYARAKAT DI INDONESIA Mukti, Ali Ghufron
Jurnal Manajemen Pelayanan Kesehatan Vol 4, No 03 (2001)
Publisher : Jurnal Manajemen Pelayanan Kesehatan

Show Abstract | Download Original | Original Source | Check in Google Scholar | Full PDF (1732.323 KB)

Abstract

TERSEDIA DALAM FILE
Skema Pelayanan Kesehatan Pra-Upaya Sebagai Strategi Keluar Dari Permasalahan Pemberhentian Program Jaring Pengaman Sosial Bidang Kesehatan Di DIY Mukti, Ali Ghufron
Jurnal Manajemen Pelayanan Kesehatan Vol 5, No 01 (2002)
Publisher : Jurnal Manajemen Pelayanan Kesehatan

Show Abstract | Download Original | Original Source | Check in Google Scholar | Full PDF (552.811 KB)

Abstract

TERSEDIA DALAM FILE
KEMAMPUAN DAN KEMAUAN MEMBAYAR PREMI ASURANSI KESEHATAN DI KABUPATEN GUNUNG KIDUL Mukti, Ali Ghufron
Jurnal Manajemen Pelayanan Kesehatan Vol 4, No 02 (2001)
Publisher : Jurnal Manajemen Pelayanan Kesehatan

Show Abstract | Download Original | Original Source | Check in Google Scholar

Abstract

TERSEDIA DALAM FILE
Dari Evidance Based Medicine Menuju Evidence Based Public Health Policy Mukti, Ali Ghufron
Jurnal Manajemen Pelayanan Kesehatan Vol 5, No 03 (2002)
Publisher : Jurnal Manajemen Pelayanan Kesehatan

Show Abstract | Download Original | Original Source | Check in Google Scholar

Abstract

TERSEDIA DALAM FILE
STUDI KASUS PROGRAM PENDIDIKAN PASCASARJANA DALAM KEDOKTERAN KELUARGA DI UNIVERSITAS KEBANGSAAN MALAYSIA Mukti, Ali Ghufron
Jurnal Manajemen Pelayanan Kesehatan Vol 3, No 04 (2000)
Publisher : Jurnal Manajemen Pelayanan Kesehatan

Show Abstract | Download Original | Original Source | Check in Google Scholar | Full PDF (6146.601 KB)

Abstract

TERSEDIA DALAM FILE
BERBAGAI MODEL ALTERNATIF SISTEM PENYELENGGARAAN ASURANSI KESEHATAN DI INDONESIA Mukti, Ali Ghufron
Jurnal Manajemen Pelayanan Kesehatan Vol 3, No 01 (2000)
Publisher : Jurnal Manajemen Pelayanan Kesehatan

Show Abstract | Download Original | Original Source | Check in Google Scholar | Full PDF (621.408 KB)

Abstract

TERSEDIA DALAM FILE
Faktor-Faktor yang Mempengaruhi Biaya Obat Pasien Kanker Payudara di Rumah Sakit di Indonesia Puspandari, Diah Ayu; Mukti, Ali Ghufron; Kusnanto, Hari
Jurnal Kebijakan Kesehatan Indonesia Vol 4, No 3 (2015)
Publisher : Center for Health Policy and Management

Show Abstract | Download Original | Original Source | Check in Google Scholar | Full PDF (198.51 KB) | DOI: 10.22146/jkki.v4i3.36110

Abstract

Background: Currently non communicable disease becomes one of the ten major diseases in Indonesia. Cancer chemotherapy reported as the ninth rank out of ten major diseases, and shared as the ten most expensive hospital cost. Drugs expenditures are clearly the main source of cost pressure. Drug cost of breast cancer is important for benefit package design. Objectives: The research need to know on what are the influencing factors of drug cost for breast cancer during hospitalization in Indonesia, and the drug cost based on the selected factors. Research Methodology : The design of research was a cross sectional descriptive analysis using health facilities costing study that was conducted in Indonesia in 2011. The drug cost was calculated as a cost of illness based on a provider’s perspective. Results: Determinant factors for drug cost in breast cancer were age, length of stay, ICU, drugs availability and hospital location. The most expensive was the drug cost for patient at age 40 - <70. Drug cost for patient with ICU care found 1,8 times higher. Hospitals who had a drug supply problems were lower in cost. Hospital in Java had a lower cost. Conclusions: Age, length of stay, ICU, drugs availability and hospital location were the determinant factors of drug cost for hospitalized breast cancer patient. Drug cost for in-patient that was based on actual cost was Rp. 2,545,881,- . Drug cost for out patient care was Rp 9,127,824,-. The total drug cost per patient per year was calculated as Rp 11,673,705,- and the total drug cost for all patient per year was Rp 150,415,869,362,-. These factors will be useful for drug cost estimation purpose and for benefit package design. Latar belakang: Saat ini penyakit tidak menular merupakan salah satu dari 10 penyakit terbesar di Indonesia. Kemoterapi kanker dilaporkan di urutan ke 9 pada pasien rawat inap, serta di posisi ke 10 penyakit termahal. Biaya obat adalah komponen biaya kesehatan dengan proporsi signifikan. Biaya obat kanker payudara diperlukan dalam penentuan paket benefit JKN. Tujuan: Mengetahui faktor apa saja yang mempengaruhi biaya obat pada pasien kanker payudara di rumah sakit, dan memperoleh besaran biaya obat berdasarkan faktor-faktor yang mempengaruhinya. Metode Penelitian: Penelitian merupakan desain analisis deskriptif cross sectional menggunakan hasil studi pembiayaan fasilitas kesehatan yang dilaksanakan di Indonesia pada tahun 2011. Biaya obat dihitung sebagai cost of illness dari sisi pemberi layanan. Hasil: Variabel yang berpengaruh terhadap biaya obat adalah umur, lama dirawat, penggunaan ICU, gangguan ketersediaan obat dan lokasi rumah sakit. Biaya obat pada usia 40 -<70 tahun tertinggi. Biaya obat di ICU lebih tinggi 1,8 kali. Rumah sakit dengan gangguan ketersediaan obat lebih rendah biaya obatnya. Biaya obat di luar pulau Jawa lebih mahal. Kesimpulan: Umur, lama dirawat, penggunaan ICU, gangguan ketersediaan obat dan lokasi rumah sakit adalah faktor yang mempengaruhi biaya obat pasien kanker payudara di rumah sakit. Biaya obat rawat inap berdasarkan biaya aktual, hasilnya menunjukkan besaran Rp754.243,00 per pasien. Biaya obat untuk rawat jalan diperoleh sebesar Rp9.127.824,00. Total biaya obat per pasien per tahun adalah Rp9.882.067,00 sehingga biaya obat seluruh pasien per tahun sebesar Rp118.723.158.312,00. Faktor tersebut bermanfaat untuk estimasi biaya dan penentuan paket pengobatan pasien kanker di era JKN.
Cost-minimization analysis of intravenous sulbenicillin versus coamoxiclav for cesarean section Andayani, Tri Murti; Athijah, Umi; Mukti, Ali Ghufron
INDONESIAN JOURNAL OF PHARMACY Vol 15 No 4, 2004
Publisher : Faculty of Pharmacy Universitas Gadjah Mada, Yogyakarta, Skip Utara, 55281, Indonesia

Show Abstract | Download Original | Original Source | Check in Google Scholar | Full PDF (209.17 KB) | DOI: 10.14499/indonesianjpharm0iss0pp201-206

Abstract

The cost of antibiotic prophylaxis sulbenicillin versus coamoxiclav (in term of medication use and treatment of complications) to treat cesarean section was compared.The medical records of patient receiving intravenous sulbenicillin orcoamoxiclav for the treatment of cesarean section in PKU Muhammadiyah Hospital were retrospectively reviewed. Data were collected for patients treated from January 1, 2000 to December 31, 2000. Patient data collected included patient data based, indication of cesarean section, abdominal incision and oral antibiotics. Cost data collected included drug acquisition cost, cost of drug supplies, nursing time to administer the agents and cost of managing complication.The medical records of 98 patients were identified and reviewed. The average length of stay was 4.85 days for the sulbenicillin group and 4.90days for the coamoxiclav group. The average total including the cost of complication was Rp. 140.509 in sulbenicillin group and Rp. 376.310 in coamoxiclav group.In conclusion, the study demonstrates that intravenous coamoxiclav has a higher cost than that of intravenous sulbenicillin. This result can be used to assist institution, clinicians and pharmacists in determining the most appropriate and efficient use of drugs. These data can be a powerful tool to support various clinical and policy drug use decisions, for example included formulary management and drug use policy or guidelines.Key words: antibiotics, cesarean section, cost.
COST ANALYSIS OF CHRONIC KIDNEY DISEASE TREATMENT INPATIENT AS CONSIDERATION DETERMINATION IN HEALTH FINANCING BASED ON INA-DRG IN Dr MOEWARDI HOSPITAL Yani, Fina Ratih Wira Putri Fitri; Mukti, Ali Ghufron; Sudjaswadi, Riswaka
JURNAL MANAJEMEN DAN PELAYANAN FARMASI (Journal of Management and Pharmacy Practice) Vol 1, No 2
Publisher : Faculty of Pharmacy, Universitas Gadjah Mada

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.22146/jmpf.32

Abstract

Application of INA-DRG (Indonesian Diagnosis Related Group) system for class III of Jamkesmas’s patientsin the hospital has the objective to health services become more effective and efficient both in terms of treatmentand cost planning. The research objective was to analyze the cost of care of patients with Chronic Renal Disease(CRD), find out the relationship between patient factors, concomitant diseases and length of stay with the cost oftreatment and know the difference between the average cost of treatment of CRD according Dr Moewardi Hospital’s tariff and INA –DRG’s package tariff.The study was descriptive and using retrospective data. The subject is limited on class III of Jamkesmas’s patientwith the same period. Variables include demographic characteristics, concomitant diseases, length of stay, costs oftreatment (direct medical costs and direct non-medical costs), and outcome. Analysis data were done with crosstaband linear regression analysis. Result of the research shown that the average cost of treatment chronic renal disease based on Dr Moewardihospital’s tariff on the severity 1st is Rp. 2,870,300 ± Rp 1,634,320, severity 2nd is Rp. 3,659,200 ± Rp. 3,537,470and severity 3rd is Rp. 1,130,690 ± Rp 1,399,252. Average real LOS patient on the severity 1st is 7,00 days, severity2nd is 8.57 days and the severity 3rd is 7.80 days. There was no relationship between patient characteristics andconcomitant diseases with the cost of treatment in hospital, while the length of stay had a relationship withthe cost of treatment. Average treatment costs in chronic kidney failure severity1st, 2nd and 3rd lower than the tariff package INA-DRG, while the average difference in the real LOS, and average LOS INA-DRG severity levels only occurred in three. Keyword : INA-DRG, Chronic Renal Disease, Jamkesmas
COST ANALYSIS OF CHRONIC KIDNEY DISEASE TREATMENT INPATIENT AS CONSIDERATION DETERMINATION IN HEALTH FINANCING BASED ON INA-DRG IN Dr MOEWARDI HOSPITAL Yani, Fina Ratih Wira Putri Fitri; Mukti, Ali Ghufron; Sudjaswadi, Riswaka
JURNAL MANAJEMEN DAN PELAYANAN FARMASI (Journal of Management and Pharmacy Practice) Vol 1, No 2
Publisher : Faculty of Pharmacy, Universitas Gadjah Mada

Show Abstract | Download Original | Original Source | Check in Google Scholar | Full PDF (3292.742 KB) | DOI: 10.22146/jmpf.32

Abstract

Application of INA-DRG (Indonesian Diagnosis Related Group) system for class III of Jamkesmas’s patientsin the hospital has the objective to health services become more effective and efficient both in terms of treatmentand cost planning. The research objective was to analyze the cost of care of patients with Chronic Renal Disease(CRD), find out the relationship between patient factors, concomitant diseases and length of stay with the cost oftreatment and know the difference between the average cost of treatment of CRD according Dr Moewardi Hospital’s tariff and INA –DRG’s package tariff.The study was descriptive and using retrospective data. The subject is limited on class III of Jamkesmas’s patientwith the same period. Variables include demographic characteristics, concomitant diseases, length of stay, costs oftreatment (direct medical costs and direct non-medical costs), and outcome. Analysis data were done with crosstaband linear regression analysis. Result of the research shown that the average cost of treatment chronic renal disease based on Dr Moewardihospital’s tariff on the severity 1st is Rp. 2,870,300 ± Rp 1,634,320, severity 2nd is Rp. 3,659,200 ± Rp. 3,537,470and severity 3rd is Rp. 1,130,690 ± Rp 1,399,252. Average real LOS patient on the severity 1st is 7,00 days, severity2nd is 8.57 days and the severity 3rd is 7.80 days. There was no relationship between patient characteristics andconcomitant diseases with the cost of treatment in hospital, while the length of stay had a relationship withthe cost of treatment. Average treatment costs in chronic kidney failure severity1st, 2nd and 3rd lower than the tariff package INA-DRG, while the average difference in the real LOS, and average LOS INA-DRG severity levels only occurred in three. Keyword : INA-DRG, Chronic Renal Disease, Jamkesmas